See more : Techcential International Ltd (6616.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Rhythm Pharmaceuticals, Inc. (RYTM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rhythm Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- J D Wetherspoon plc (JDWPY) Income Statement Analysis – Financial Results
- Union Materials Corp. (047400.KS) Income Statement Analysis – Financial Results
- Chibougamau Independent Mines Inc. (CMAUF) Income Statement Analysis – Financial Results
- Taylor Wimpey plc (TWODF) Income Statement Analysis – Financial Results
- Voyager Metals Inc. (VDMRF) Income Statement Analysis – Financial Results
Rhythm Pharmaceuticals, Inc. (RYTM)
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.43M | 23.64M | 3.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 9.30M | 2.13M | 599.00K | 690.00K | 834.00K | 442.00K | 223.00K | 144.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 68.13M | 21.51M | 2.56M | -690.00K | -834.00K | -442.00K | -223.00K | -144.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 87.99% | 90.98% | 81.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 134.95M | 108.63M | 104.13M | 90.45M | 109.45M | 50.34M | 22.89M | 19.59M | 7.15M | 5.28M | 18.02M | 15.68M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.08M | 9.52M | 6.31M | 3.43M | 1.21M | 3.43M | 2.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 117.53M | 92.03M | 68.49M | 46.13M | 36.55M | 28.08M | 9.52M | 6.31M | 3.43M | 1.21M | 3.43M | 2.46M |
| Other Expenses | 0.00 | -790.00K | 100.00M | 0.00 | 0.00 | 0.00 | -1.86M | 0.00 | -500.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 252.48M | 200.66M | 172.61M | 136.58M | 146.00M | 78.42M | 32.41M | 25.91M | 10.57M | 6.49M | 21.45M | 18.14M |
| Cost & Expenses | 261.79M | 202.80M | 173.21M | 136.58M | 146.00M | 78.42M | 32.41M | 25.91M | 10.57M | 6.49M | 21.45M | 18.14M |
| Interest Income | 13.95M | 4.03M | 447.00K | 2.58M | 5.27M | 4.35M | 566.00K | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.89M | 5.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.76M | 1.40M | 1.16M | 690.00K | 834.00K | 442.00K | 223.00K | 144.00K | 500.00K | 6.49M | 20.00K | 17.00K |
| EBITDA | -168.46M | -174.52M | -68.45M | -135.89M | -145.17M | -77.98M | -32.19M | -25.76M | -10.07M | 0.00 | -21.41M | -18.12M |
| EBITDA Ratio | -217.58% | -744.22% | -5,391.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -184.36M | -179.16M | -170.06M | -136.58M | -146.00M | -78.42M | -32.41M | -25.91M | -10.57M | -6.49M | -21.45M | -18.14M |
| Operating Income Ratio | -238.10% | -757.92% | -5,391.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 243.00K | -1.96M | 100.45M | 2.58M | 5.27M | 4.35M | -1.30M | 33.00K | -500.00K | 0.00 | 17.00K | 8.00K |
| Income Before Tax | -184.11M | -181.12M | -69.61M | -134.00M | -140.73M | -74.06M | -33.71M | -25.87M | -11.07M | -6.49M | -21.43M | -18.13M |
| Income Before Tax Ratio | -237.79% | -766.22% | -2,207.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 564.00K | 1.96M | -1.61M | -3.27M | -6.11M | 4.35M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -184.68M | -183.08M | -68.01M | -130.73M | -134.62M | -74.06M | -33.71M | -25.87M | -11.07M | -6.49M | -21.43M | -18.13M |
| Net Income Ratio | -238.52% | -774.52% | -2,156.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.20 | -3.51 | -1.37 | -2.96 | -3.70 | -2.39 | -2.54 | -1.55 | -0.66 | -0.64 | -0.43 | -0.36 |
| EPS Diluted | -3.20 | -3.51 | -1.37 | -2.96 | -3.70 | -2.39 | -2.54 | -1.55 | -0.66 | -0.64 | -0.43 | -0.36 |
| Weighted Avg Shares Out | 57.67M | 52.12M | 49.60M | 44.13M | 36.42M | 31.00M | 13.27M | 16.73M | 16.73M | 10.20M | 50.27M | 50.27M |
| Weighted Avg Shares Out (Dil) | 57.67M | 52.12M | 49.60M | 44.13M | 36.42M | 31.00M | 13.27M | 16.73M | 16.73M | 10.20M | 50.27M | 50.27M |
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals Announces Update to September Conference Participation
Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome
Rhythm Pharmaceuticals to Present at Investor Conferences in September
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals: A Virtual Monopoly In Orphan Obesity Disorders
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2023 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update
Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome
Source: https://incomestatements.info
Category: Stock Reports